Cotempla Xr-odt Tablet, Orally Disintegrating
NDC Package 70165-100-31

11-digit billing NDC: 70165010031

Package Information

Cotempla Xr-odt (methylphenidate) tablets is cOTEMPLA XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age [see Clinical Studies (14)]. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Neos Therapeutics Brands, Llc, this product is identified by NDC 70165-100 and is authorized under FDA application NDA205489.

Identification & Billing

NDC Package Code
70165-100-31
Package Description
30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
Product Code
11-Digit Billing Format
70165010031
RxNorm Crosswalk
  • RxCUI: 1926840 - methylphenidate 17.3 MG Extended Release Disintegrating Oral Tablet
  • RxCUI: 1926840 - methylphenidate 17.3 MG Disintegrating Oral Tablet
  • RxCUI: 1926847 - Cotempla XR-ODT 17.3 MG Extended Release Disintegrating Oral Tablet
  • RxCUI: 1926847 - methylphenidate 17.3 MG Disintegrating Oral Tablet [Cotempla]
  • RxCUI: 1926847 - Cotempla 17.3 MG Disintegrating Oral Tablet

Clinical Specifications

Proprietary Name
Cotempla Xr-odt
Non-Proprietary Name
Methylphenidate
Substance Name
Methylphenidate
Dosage Form
Tablet, Orally Disintegrating - A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
COTEMPLA XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age [see Clinical Studies (14)]. Limitations of UseThe use of COTEMPLA XR-ODT is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7). Use in Specific Populations (8.4)].
DEA Schedule
Schedule II (CII) Substances

Regulatory & Marketing

Labeler Name
Neos Therapeutics Brands, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA205489
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-20-2017
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70165-100). Click a package code to view its specific billing and regulatory data.

5 BLISTER PACK in 1 CARTON / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70165-100-31 identifies a specific commercial package of 30 tablet, orally disintegrating in 1 bottle of Cotempla Xr-odt, a human prescription drug labeled by Neos Therapeutics Brands, Llc. This tablet, orally disintegrating is formulated for oral use and contains methylphenidate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Neos Therapeutics Brands, Llc on June 20, 2017. The current certification is valid through December 31, 2027.

How is this Neos Therapeutics Brands, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70165010031. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70165-100-31
11-Digit CMS (5-4-2)
70165-0100-31

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.